APA

Traboulsee A., Greenberg B. M., Bennett J. L., Szczechowski L., Fox E., Shkrobot S., Yamamura T., Terada Y., Kawata Y., Wright P., Gianella-Borradori A., Garren H. & Weinshenker B. G. (20200721). Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. : The Lancet. Neurology.

Chicago

Traboulsee Anthony, Greenberg Benjamin M, Bennett Jeffrey L, Szczechowski Lech, Fox Edward, Shkrobot Svitlana, Yamamura Takashi, Terada Yusuke, Kawata Yuichi, Wright Padraig, Gianella-Borradori Athos, Garren Hideki and Weinshenker Brian G. 20200721. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. : The Lancet. Neurology.

Harvard

Traboulsee A., Greenberg B. M., Bennett J. L., Szczechowski L., Fox E., Shkrobot S., Yamamura T., Terada Y., Kawata Y., Wright P., Gianella-Borradori A., Garren H. and Weinshenker B. G. (20200721). Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. : The Lancet. Neurology.

MLA

Traboulsee Anthony, Greenberg Benjamin M, Bennett Jeffrey L, Szczechowski Lech, Fox Edward, Shkrobot Svitlana, Yamamura Takashi, Terada Yusuke, Kawata Yuichi, Wright Padraig, Gianella-Borradori Athos, Garren Hideki and Weinshenker Brian G. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. : The Lancet. Neurology. 20200721.